Solvay requests FDA hearing regarding Estratest
Executive Summary
Solvay requests hearing with FDA regarding its combination estrogen/methyltestosterone product Estratest and its pending ANDA for Estratest H.S. The company is responding to an April 14 notice in the Federal Register that announced FDA's proposal to withdraw the vasomotor symptoms indication for all androgen/estrogen combination agents. The agency is encouraging manufacturers to provide data about new uses, such as female sexual dysfunction, in order to keep the products on the market (1"The Pink Sheet" April 14, 2003, p. 17)...
You may also be interested in...
Solvay Estratest Female Sexual Dysfunction Studies Could Save Product – FDA
Solvay should provide studies supporting the use of Estratest (estrogen/methyltestosterone) for the treatment of female sexual dysfunction to keep the product on the market, FDA suggests
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.